Publicly-traded company Amneal Pharmaceuticals Inc. (NYSE:AMRX) had a closing price of $2.76 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $4.71, this means that the stock is underpriced by 41.4%. In the past 52 weeks the company’s stock price has moved within the range of $2.27 to $21.22.
This particular stock’s 5-day moving average is 3.23, its 20-day moving average is 3.08 and its 100-day moving average is 3.67. Amneal Pharmaceuticals Inc. (AMRX) currently has 268.57M shares outstanding, which means that its market capitalization is $741.25M.
The Details: Amneal Pharmaceuticals Inc. (AMRX) Financial Health
There are numerous indicators we can use to give us a better idea about a public company’s financial health. For instance, we can check out the profit margin, which tells us about how much of a company’s net sales it keeps as earnings. We find this figure by dividing net income by net sales. AMRX currently has a profit margin of -3.60%.
It can also be helpful to look at a public company’s operating margin, which shows us how much profit the company retains after taking depreciation and operating expenses into account. Amneal Pharmaceuticals Inc. (AMRX) has an operating margin of -0.60%.
It is also smart to find out what a company’s Return on Assets is. This percentage tells us how well a company is making use of its net assets to generate a profit. The lower the percentage, the worse the company does with its available assets. At the moment, Amneal Pharmaceuticals Inc. Return on Assets is -1.50%.
What Does Wall Street Say about Company?
When considering a new stock purchase, a lot of investors find out how Wall Street analysts feel about the company before they buy in. You can do this by looking for the average analyst rating on the company’s stock. At the moment, the average analyst rating for AMRX is Overweight. Out of 13 total analysts who were surveyed, 1 rated it a sell, 0 rated it a underweight, 1 rated it an overweight, 6 rated it hold, and 5 rated it a Buy.
Three months ago, on the other hand, the average analyst rating for Amneal Pharmaceuticals Inc. (AMRX) was a Overweight – from a survey of 13 analysts. Of the analysts who provided ratings, 8 rated the company a Hold, 0 rated it a Sell, 0 rated it an overweight, 0 rated it an underweight, and 5 rated it a Buy.
Understanding Profitability at Amneal Pharmaceuticals Inc. (AMRX)
Having a look at a company’s recent Earnings per Share (EPS) performance is a useful way of understanding its profitability. In the most recent financial results released by Amneal Pharmaceuticals Inc., for the quarter ending on 09/2019, the company posted EPS of 0.11. The average estimate of Wall Street analysts had projected 0.13.
Wall Street analysts, on average, are forecasting the company’s EPS to be 0.14, compared to 0.28 reported in the same quarter last year.